128 related articles for article (PubMed ID: 6678971)
1. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
Feun LG; Savaraj N; Lu K; Guo Z; Raulston LG; Benjamin RS; Fields WS; Loo TL
J Neurooncol; 1983; 1(3):219-24. PubMed ID: 6678971
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ).
Lu K; Savaraj N; Yap BS; Bedikian AY; Feun L; Benjamin RS; Loo TL
Eur J Cancer Clin Oncol; 1983 May; 19(5):603-6. PubMed ID: 6683631
[TBL] [Abstract][Full Text] [Related]
3. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).
Savaraj N; Lu K; Feun LG; Leavens ME; Stewart D; Burgess MA; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(1):15-9. PubMed ID: 6678302
[TBL] [Abstract][Full Text] [Related]
4. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
Egorin MJ; Bellis EH; Salcman M; Collins JM; Spiegel JF; Bachur NR
J Neurosurg; 1984 May; 60(5):1005-13. PubMed ID: 6716135
[TBL] [Abstract][Full Text] [Related]
5. Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
Bachur NR; Collins JM; Kelley JA; Van Echo DA; Kaplan RS; Whitacre M
Clin Pharmacol Ther; 1982 May; 31(5):650-5. PubMed ID: 7075113
[TBL] [Abstract][Full Text] [Related]
6. Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid.
Gormley PE; Wood JH; Poplack DG
Pharmacology; 1981; 22(3):196-8. PubMed ID: 7208602
[TBL] [Abstract][Full Text] [Related]
7. Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Gutierrez PL; Egorin MJ; Fox BM; Friedman R; Bachur NR
Biochem Pharmacol; 1985 May; 34(9):1449-55. PubMed ID: 3994758
[TBL] [Abstract][Full Text] [Related]
8. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Spiegel JF; Egorin MJ; Collins JM; Lerner BD; Bachur NR
Drug Metab Dispos; 1983; 11(1):41-6. PubMed ID: 6132794
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of diaziquone after three different dosage regimens.
Bjornsson TD; Schold SC; Friedman HS; Schneider D; Falletta JM
Cancer Treat Rep; 1985 Dec; 69(12):1383-5. PubMed ID: 4075314
[TBL] [Abstract][Full Text] [Related]
10. Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).
King CL; Wong SK; Loo TL
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):261-4. PubMed ID: 6538490
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
Zimm S; Collins JM; Curt GA; O'Neill D; Poplack DG
Cancer Res; 1984 Apr; 44(4):1698-701. PubMed ID: 6704975
[TBL] [Abstract][Full Text] [Related]
12. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
[TBL] [Abstract][Full Text] [Related]
13. The lack of correlation between toxicity and free radical formation of two diaziridinyl benzoquinones.
Lea JS; Garner HJ; Butler J; Hoey BM; Ward TH
Biochem Pharmacol; 1988 May; 37(10):2023-5. PubMed ID: 2837220
[TBL] [Abstract][Full Text] [Related]
14. Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Gutierrez PL; Friedman RD; Bachur NR
Cancer Treat Rep; 1982 Feb; 66(2):339-42. PubMed ID: 6275990
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial toxicity of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzoquinone.
Oberc-Greenwood MA; Smith BH; Cooke C; Ellis JR; Kornblith PL; McKeever PE
J Natl Cancer Inst; 1983 Oct; 71(4):725-33. PubMed ID: 6578368
[TBL] [Abstract][Full Text] [Related]
17. Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs.
Wright KC; Stephens LC; Wallace S; Savaraj N; Feun LG
Chemotherapy; 1987; 33(6):437-44. PubMed ID: 3428010
[TBL] [Abstract][Full Text] [Related]
18. The reduction of anti-tumour diaziridinyl benzoquinones.
Butler J; Hoey BM; Lea JS
Biochim Biophys Acta; 1987 Aug; 925(2):144-9. PubMed ID: 3040109
[TBL] [Abstract][Full Text] [Related]
19. Mechanism(s) of bioreductive activation. The example of diaziquone (AZQ).
Gutierrez PL
Free Radic Biol Med; 1989; 6(4):405-45. PubMed ID: 2651223
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
